The TRITON2 phase II study of rucaparib enrolled 192 mCRPC patients with disease progression after one or two lines of androgen receptor pathway inhibitors (ARPIs), as well as prior taxane chemotherapy with deleterious germline or somatic alterations in HRR genes, to a BRCA1/2 (n = 115) and non-BRCA (n = 78) cohort of 13 other genes, including ATM, CDK12, CHEK2, FANCA, PALB2, and RAD51, using tissue or circulating tumour DNA assay [8,9,34]. This evidence concerns the gene AR and neoplasm.